Background In the context of an aging population with increasing diabetes prevalence, people are living longer with diabetes, which leads to increased multimorbidity and economic burden. Objective The primary aim was to explore different strategies that address the economic impact of multiple type 2 diabetesrelated complications and their interactions. Methods We used a generalized estimating equations approach based on nationwide statutory health insurance data from 316,220 patients with type 2 diabetes (baseline year 2012, 3 years of follow-up). We estimated annual total costs (in 2015 euros) for type 2 diabetes-related complications and, in addition, explored different strategies to assess diabetes-related multimorbidity: number of prevalent complications, co-occurrence of micro-and macrovascular complications, disease-disease interactions of prevalent complications, and interactions between prevalent/incident complications. Results The increased number of complications was significantly associated with higher total costs. Further assessment of interactions showed that macrovascular complications (e.g., chronic heart failure) and high-cost complications (e.g., end-stage renal disease, amputation) led to significant positive effects of interactions on costs, whereas early microvascular complications (e.g., retinopathy) caused negative interactions. The chronology of the onset of these complications turned out to have an additional impact on the interactions and their effect on total costs. Conclusions Health economic diabetes models and evaluations of interventions in patients with diabetes-related complications should pay more attention to the economic effect of specific disease interactions. Politically, our findings support the development of more integrated diabetes care programs that take better account of multimorbidity. Further observational studies are needed to elucidate the shared pathogenic mechanisms of diabetes complications.
Introduction
Type 2 diabetes is not only becoming increasingly prevalent worldwide (7% in Germany in 2011), but is also emerging as an important comorbidity in daily clinical practice [1, 2] . Demographic changes as well as improved prognosis of life-threatening and chronic diseases (e.g., myocardial infarction [MI] , renal insufficiency) are contributing to an aging population with diabetes and growing multimorbidity. In response to the arising economic challenges, the term "high-need, high-cost" has been introduced in recent years to characterize a growing group of usually older patients who are suffering from multiple diseases such as diabetes, require multiple medications, and tend to have more frequent health behavior problems and hospital admissions. What is lacking in the literature is a systematic analysis of the impact of diabetes-related multimorbidity and underlying heterogeneity from disease interactions on healthcare costs [3] . Statistically, such disease interactions can have a positive or negative effect on the outcome variable (costs, clinical outcomes and quality of life), which means that the effect of the co-occurring diseases is either more or less than could be expected from their individual effects. In detail, the typical multimorbidity cluster in diabetes patients is characterized by one or more of the following diabetes-related acute or chronic complications: coronary heart disease (CHD), chronic heart failure (CHF), stroke, retinopathy, renal insufficiency, and peripheral vascular disease [4] . It is to be expected that the coexistence of multiple diseases will be a major contributing factor to the increasing economic burden of diabetes, which is currently estimated at US$1.3 trillion worldwide [5] . Therefore, to conduct thorough health economic evaluations of new diabetes and complication treatments or prevention programs, diabetes models that consider complex interaction patterns are becoming increasingly important. Two of the best known non-commercial international type 2 diabetes models are the UK Prospective Diabetes Study (UKPDS) model and the model developed by the Center for Disease Control and Prevention/Research Triangle Institute (CDC/RTI) [6, 7] . For example, the CDC/RTI model uses five individual disease paths for the most common complications and integrates their interactions through a faster progression on these paths (e.g., presence of hypertensive nephropathy leads to faster progression of chronic heart disease compared to the absence of nephropathy). As another example, a study of UKPDS data found no significant effect of the co-occurrence of complications on patient's quality of life [8] , whereas a German study showed that patients with diabetes, coronary events, and a history of stroke had a worse quality of life than could be expected from the separate effects [9] . However, there are only limited data and evidence to inform diabetes models about the economic consequences of disease interactions [10] . Due to their special focus and time-and budget-restricted nature, randomized trials, if they investigate interactions at all, generally concentrate on interactions between frequent outcomes. Moreover, in Germany, data sources such as routinely collected statutory health insurance (SHI) data may be better suited because of their large sample size, extensive population coverage (around 90%), and detailed cost data over several years [11] .
The primary aim of this study was to use a large claims data set to explore regression-based strategies for analyzing the economic impact of multiple type 2 diabetes-related complications and their interactions on total costs. A secondary purpose of this study is to describe the patterns of these disease interactions. This study builds on a previous study, where we presented the data together with a longitudinal analysis of quarterly costs for incident complications, but without considering interactions [12] . In addition to presenting new empirical evidence for Germany, this study has a strong methodological focus that addresses data accuracy issues and differentiates between the co-occurrence of prevalent complications or disease groups and the development of incident complications on top of prevalent complications. Our methodology and findings will serve as an important input for data scientists, and especially developers of diabetes and related models.
Methods

Data and Research Design
A core component of Germany's healthcare system is its SHI, covering ~ 90% of the population. This retrospective cohort study is based on data from the largest SHI provider in Germany, the Techniker Krankenkasse (TK), which included around 10 million insured people in 2017. In addition to basic demographic data, the claims contain detailed information on, for example, healthcare costs, outpatient and inpatient diagnoses and procedures, and medication data. Although outpatient diagnoses are only documented on a quarterly level, admission and discharge dates are available for inpatient data. The selection of type 2 diabetes patients was defined on the basis of two outpatient diagnoses in two different quarters and/or one inpatient diagnosis (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification [ICD-10-GM] codes E11 and E14), prescription of oral antidiabetics, and participation in a disease management program for type 2 diabetes. All patients who met the inclusion criteria and passed the exclusion criteria in the baseline year (2012) were included in the analysis. Full details on the iterative selection algorithm were published recently [12] (a summary can be found in the electronic supplementary material; see "Supplementary Appendix I" on the "selection of study population"). The follow-up period of this study covered 3 years, from 2013 to 2015, so that every person had up to three observations, one for each calendar year. The whole time horizon is 4 years, because outpatient service data are only stored for a limited time, according to social laws. Healthcare costs include outpatient and inpatient services, medication, rehabilitation, and the provision of aids and appliances. All costs are expressed in 2015 euros using official inflation data from the Federal Statistical Office (14).
Choice and Identification of Prevalent and Incident Complications
The following complications were considered and are characteristically used in diabetes models, such as the CDC/RTI model and the UKPDS outcomes model: macrovascular complications, including angina pectoris, CHF, MI/cardiac arrest (CA), stroke, and other ischemic heart diseases (IHD), and microvascular complications including retinopathy, blindness, diabetic foot, lower extremity amputation, nephropathy, and end-stage renal disease (ESRD). All these complications are known to belong to the most common comorbidity clusters among patients with diabetes [4] . The complications were identified based on ICD diagnoses and outpatient and inpatient procedure codes (see Table S1 in the electronic supplementary material or the previous publication) [12] . A distinction can be made between prevalent and incident complications in order to address different research aspects (descriptive and causal). The definition of prevalent complications required that at least one outpatient or one primary or secondary inpatient ICD diagnosis was documented in a specific year at baseline or follow-up [12] . Uncertain diagnoses were not considered. In the case of acute macrovascular complications (MI/CA, stroke, and IHD), only hospitalizations with a primary diagnosis were considered. On the other hand, the definition of incident complications additionally required that patients were free from diagnoses of the disease at baseline (2012). Otherwise, patients were defined as having a prevalent history of the complication, which was assumed to continue throughout the follow-up.
Strategies to Address Diabetes-Related Multimorbidity and Interactions
Figure S1 (see the electronic supplementary material) shows important analytical aspects of multimorbidity, including the type of measurement, chronology of diseases, differentiation between diabetes-related complications and unrelated comorbidities, effect of interactions, and subgroup effects.
As this study focuses on diabetes-related multimorbidity, four different strategies were explored to develop a comprehensive yet granular understanding of the economic effect of co-occurring complications and their specific interactions. Before looking at specific pairwise interactions, we start with the most common method in the literature to indicate whether the presence of multimorbidity is associated with higher costs.
• Strategy 1 evaluates diabetes-related multimorbidity by simply counting multiple prevalent complications (i.e., two, three, or more complications). It makes the assumption of independence of the type of complication and is helpful for comparison reasons.
To add complexity, the next two strategies considered interactions between groups of prevalent complications or single prevalent complications in each year.
• Strategy 2 divides the spectrum of complications into two main pathophysiological groups (microvascular and macrovascular) without looking at the relationship between specific complications [13] .
• Strategy 3 looks at specific interactions of prevalent complications (e.g., between present retinopathy and diabetic foot).
Finally, the last strategy helps to understand the possible chronological dependence structure of diabetes-related multimorbidity and temporal causality of interactions.
• Strategy 4 distinguishes between chronic complications that were present since baseline and incident complications that started or occurred in the follow-up (e.g., prevalent CHF since baseline and incident MI in the follow-up). Interactions between prevalent and incident complications are referred to as sequential interactions.
Data Accuracy and Interaction Patterns Emerging from the Data
There are two important issues arising from the data that we have to address in this study of the influence of interaction patterns on healthcare costs. The first is that we have to decide whether different stages of the same disease in a given time period contribute to multimorbidity. The second is that claims data by nature only reflect real-world clinical practice records; to improve data accuracy, it can be necessary to correct irregular diagnostic patterns of chronic diseases. On the first point, in the annual cross-sectional data, there is a strong correlation between ESRD and nephropathy, amputation and foot complications, and blindness and retinopathy, which practically means that the majority of patients with ESRD, amputation, or blindness were also diagnosed with the earlier stages of the complication in the same year (but not vice versa). This is not surprising as it reflects the natural progression of complications, e.g., a foot ulcer normally precedes an amputation. Similarly, in a Markov model setting, patients are always modeled as transitioning from an early to an advanced stage. In order to avoid a multimorbidity problem between conditions of the same complication family, we applied this perspective and considered the advanced stage of a complication (ESRD, blindness, amputation) in years with two competing diagnoses. On the second point, in the longitudinal view, there can be gaps in the diagnostic validity of chronic complications (retinopathy/ blindness, nephropathy/ESRD, CHF, angina pectoris, diabetic foot) resulting from incomplete coding of diagnoses by physicians and irregular visits to the doctor (see Table S2 in the electronic supplementary material). For example, a chronic diagnosis was recorded in 2013 and 2015, but was missing in 2014. These types of gaps of one or more years can be interpreted as possible missing information, which can influence the analysis of interaction patterns. We therefore examined the effect of different algorithms to impute for such possible missing diagnoses (details on the imputation routine and our rationales can be found in "Supplementary Appendix II" in the electronic supplementary material). It was decided, based on preliminary regression analyses of the observed and imputed data, to correct for missing diagnoses in the chronic history of diabetic foot and retinopathy. For all other conditions, the original diagnoses data were used.
Statistical Analysis
To account for the non-independence of observations within each subject, we used a generalized estimating equations (GEE) model with a first-order autocorrelation structure (AR (1)). A near normality of the sample means was assumed. This assumption is justified by literature recommendations, based on the large sample size and the relatively low proportion of zero costs (< 2%) [14] . In addition, the additive approach has been verified to provide a better model fit based on the mean square error compared with a multiplicative model with a gamma log-link GEE model where €1 was assigned for patients with zero costs. Strategies 1-3 are based on a prevalence approach, which leads to the following set of variables (see "Statistical Appendix" in the electronic supplementary material for full model notation): age (in five age groups), sex, age-sex interaction, presence of different complications, plus the number of complications or interactions (according to the strategy). Strategy 4 leads to the extended set of the following variables: age groups, sex, age-sex interaction, occurrence of different incident complications, presence of prevalent chronic complications at baseline, plus sequential interactions. For strategies 3 and 4, which require careful variable selection, interactions were included using a stepwise approach based on a p value of 0.05 [15] . All analyses were performed at the Scientific Institute of TK for Benefit and Efficiency in Health Care (WINEG) that approved the intended use of the data.
Results
Sample Characteristics
The study sample included 316,220 patients with a mean age of ~ 66 years; over 60% of them were men. The baseline characteristics in Table 1 provide a first indication that multimorbidity is associated with different population characteristics. Out of the total population, 61% had no complications at baseline, 26% had one complication, and 13% had at least two or more complications. It was found that the proportion of men rises with the number of complications (~ 69% in the group with at least two complications). Similarly, the mean age and share of participants in a structured disease management program for type 2 diabetes is the highest in this group, with over 72% and approximately 72 years. The proportion of patients receiving no antidiabetic treatment was maximal (~ 42%) in the group with no complications, whereas the proportion of an insulin-based therapy (insulin only or combined with oral agents) is highest in the group with two or more complications (~ 35%). Regarding other comorbidities and risk factors, hypertension is the most frequent, with around 98% in the group with two or more complications compared with the overall average of ~ 86%. Figure 1 shows what the diabetes-related multimorbidity network looks like in this population. The 3-year prevalence rates of the complications (2013-2015) are mapped as well as the most frequent interactions between different types of complications. Further details on the frequencies of interactions can be found in Table S3 (see the electronic supplementary material). We did not include hypertension because the majority already had diagnosed hypertension or received antihypertensive agents. Nephropathy (~ 28%), CHF (~ 23%), and foot complications (22%) had the highest 3-year prevalence. Owing to the higher frequency, the cooccurrence of these conditions is also more likely. Nephropathy and CHF is the most frequent interaction (41% of CHF observations), followed by nephropathy and foot complications (37% of diabetic foot observations), and retinopathy and foot complications (25% of retinopathy observations). It is also noticeable that most cardio-and cerebrovascular conditions are likely to appear together with nephropathy and CHF. Tables 2 and 3 show the results for strategies 1-3 that are based on a cross-sectional prevalence approach. Depending on the strategy used, prevalent complications were associated with the following additional costs per year (compared with a population without complications): diabetic foot €1100-1300, amputation €18,200-20,600, retinopathy -€200 to over €200, blindness €1800-2100, nephropathy €2500-2600, ESRD €26,000-30,000, stroke €12,300-13,000, MI €6800-7700, IHD €5700-6800, angina pectoris €1000-1700, and CHF €2500-3200. In strategy 1 (Table 2) , we can only see that the number of complications (2, 3, and ≥ 4) has a significant impact on total costs. The implementation of more advanced strategies is needed to interpret specific interaction effects. In strategy 2 (Table 3) , we gain more information on the relevance of pathophysiological groups of complications (microvascular and macrovascular). Although the presence of multiple microvascular complications showed a negative effect on total costs (particularly to correct for the overestimation of inpatient costs), multiple macrovascular complications or interactions between micro-and macrovascular complications were positively associated with total costs. In addition, the size of the effect significantly depends on the number of micro-or macrovascular complications. In strategy 3, we extensively analyzed specific disease-disease interactions of prevalent conditions. Out of 52 possible interactions, 13 interactions had a significant impact on total costs. CHF has been shown to be of particular importance in the pairwise interactions (especially for cardiovascular conditions, but also for microvascular complications). Most of the interactions had a positive effect on total costs, ranging from approximately €180 for retinopathy and diabetic foot to around €13,600 for ESRD and IHD. Negative effects on total costs were found for certain interactions with retinopathy and angina pectoris. As an indicator for the economic relevance of specific interactions, Table S4 (see the electronic supplementary material) shows the relative proportions of interaction estimates to the mean estimates of complications. Generally, the percentage is far over 10%, indicating a moderate to high relevance. In (Table 4) , the sequence of specific disease-disease interactions was assessed using an incidence approach. Annual costs for incident complications ranged from €40 for retinopathy to around €26,000 for ESRD. Out of 60 possible interactions, 15 sequential interactions were found to have a significant impact on total costs. Again, history of CHF followed by ESRD was frequently involved in positive interactions. In some interactions, a history of retinopathy, diabetic foot, or angina pectoris led to a negative effect on total costs. Switching incident and historical conditions led to either reversed effects (from positive to negative and vice versa) or positive but smaller effects. Although not all these interactions were significant in the overall model, it indicates that the chronology of diseases is important.
Descriptive Analysis
Regression Analysis
Discussion
This study provides novel methodological and empirical findings on the assessment of the economic impact of multiple diabetes-related complications and their interactions. At an empirical level, there is currently no other German study providing similarly detailed cost information on modelrelevant diabetes complications. At a methodological level, there is no international study exploring the economic effect of interactions between multiple disease complications in a comparably structured way. Methodology and results on interaction patterns and economic effects can be used to inform other research in diabetes, especially health economic models or even to build a German diabetes model. The results of the regression models gradually revealed the complexity of diabetes-related multimorbidity that goes beyond the simple counting of comorbidities/complications. In detail, this study adds additional evidence for diabetes models, indicating that the effect of diabetes-related multimorbidity is less than multiplicative yet more than additive. In support of this, we systematically identified significant interactions between disease groups and single complications based on additive GEE models, where the interactions predominantly had a positive effect on total healthcare costs. Some of the interactions (such as nephropathy and CHF) had already been identified to be epidemiologically important based on a multimorbidity network. Apart from highly prevalent complications, expensive conditions (such as amputations) were also found to be more sensitive for interactions. In addition, the sequence of the occurrence of complications revealed an additional impact on the interpretation of interactions. 
Comparison and Cross-Validation with Other Studies
Direct evidence on the economic impact of diabetes-related multimorbidity, specifically on disease-disease interactions, is barely available. Although there is some international evidence indicating that costs increase gradually with the number of comorbidities/complications and higher levels of the adapted Diabetes Complications Severity Index (aDCSI) [16, 17] , detailed studies on specific interactions are lacking. In addition, there is a study that showed higher hospitalization costs for type 2 diabetes resulting from macrovascular rather than microvascular complications; however, it did not consider a combination of both [18] . Regarding specific interactions, epidemiological literature was found on associations between diabetic foot and retinopathy [19] , amputation and chronic kidney disease [20, 21] , retinopathy and chronic kidney disease [22, 23] , chronic kidney disease and cardiovascular disease [24] [25] [26] , and diabetic foot and cardio-and cerebrovascular diseases [27, 28] . Interactions were often reflected in increased severity and faster progression to more advanced stages or death. In addition, these studies support the involvement of microvascular diseases in the development of macrovascular diseases in patients with diabetes.
Interpretation and Integration of Interactions in Diabetes Models
An important point for discussion is the challenge of integrating evidence on multimorbidity in diabetes simulation models. Modeling a heterogeneous population of patients with a systemic disease and multiple complications is challenging since a complex network of patient characteristics, pathophysiological processes, and different treatment approaches have to be translated into a formal computer simulation [29] . Diabetes is one of the few examples of whole disease models, where multiple comorbidities are modeled simultaneously (e.g., using a summarized state transition matrix as in the CDC/RTI model) [30] . Although these models by nature focus on well-known diabetes-related complications, they are constantly updated as soon as new evidence emerges. In these complex structures, multimorbidity is often taken into account by including covariates (e.g., blood pressure) that have multiple effects and can thus cause interactions. The most common interactions are usually two-way disease interactions that lead to a faster progression on each of the disease paths. The detailed analysis of specific diseasedisease interactions in this study is of particular interest for cost-effectiveness analyses based on microsimulation models, as the prediction of costs in patients with specific complications can be improved. Markov cohort models, in contrast, are more focused on population mean costs of complications rather than on individual variations due to interactions. In particular, such methods and findings can be used to refine interaction patterns and assign detailed cost information to specific health states. In this context, the following assumptions and constraints have to be considered. First, the exact lapse of time between two co-occurring conditions cannot be determined; however, most of the complications are chronic, and diabetes models typically use 1-year intervals. Second, we do not account for the longitudinal development of disease interactions; however, at least in strategy 4, we were still able to integrate a time component in our analysis. In detail, most of the significant disease-disease interactions (strategy 3 and 4) were positively associated with higher costs. This can be due to several factors: causal interactions within the pathogenesis, severity, disease management, or progression (i.e., more severe in combination with renal failure, less severe in combination with retinopathy). These factors, however, do not change the interpretation of the economic effect of the interactions. Although positive interactions are often easier to interpret, it has to be considered for negative interactions that certain costs may be covered in the main estimates, so that negative interactions reduce double counting of costs. One reason for possible double counting is that total cost estimates include inpatient costs for hospital admissions due to primary and other (secondary) diagnoses (e.g., CHF and retinopathy). In addition, negative interactions are influenced by the severity of complications that can be different depending on the presence of early stages of other conditions (e.g., CHF with concurrent retinopathy may be less severe than average CHF). Beyond the interpretation of the direction of interactions (positive or negative), it is important to understand the economic relevance of specific disease interactions. Our study could show that just counting complications (strategy 1) is not sufficient to dissect and quantify potential interactions within multimorbidity. In the example of two complications, estimated additional costs were relatively low because all types of complications and their (significant and non-significant) interactions are mixed up in one estimate. Therefore, the usefulness of a model strategy is not only a question of the goodness-of-fit, but highly depends on the intended purpose of analysis (e.g., as adjustment variable for prediction, or to investigate the underlying effects of diabetes-related multimorbidity).
Further Strengths and Weaknesses of this Study
Among the core strengths of this study is its large population size that is less vulnerable to outliers. The analysis was based on real-world data from a nationwide health insurance fund that can be regarded as the best available data source for healthcare costs in Germany. However, some limitations must be considered. These include a lack of clinical data (e.g., severity), unknown duration of diabetes, and reliance on diagnostic accuracy. Beyond the mere comparison of sensitivity and specificity of disease definitions over multiple years in the literature [31] , we were able to specify the incomplete patterns of diagnoses and proposed a way to handle this issue in claims data. In addition, several factors can explain diagnoses restricted to 1 year, including acute episodes of chronic conditions, accidental findings, remissions, or false-positive cases.
Another key feature of this study is our effort to inform health economic diabetes models. Therefore, and to avoid an overfitting of the model, we did not adjust for other comorbidities than model-relevant complications. In addition, the included complications have been shown to make up the most important comorbidity clusters [4] . The exception is that we did not adjust for hypertension, because the vast majority of patients already had diagnosed/treated hypertension at baseline. Finally, it is important that this study primarily provides information on statistical cost interactions and can only touch upon the issue of causal interactions. Despite there being more to be done, these findings provide a broad basis for discussion and further research investigations in this area.
Future Implications
The results of this study have several implications for different healthcare stakeholders. From a modeler's perspective, future diabetes models should pay more attention to computing multimorbidity, and especially interactions, which may have a considerable effect on both health effects and costs. From a policy perspective, our findings encourage the implementation and further development of more integrated prevention and disease management programs that take better account of preexisting or co-occurring conditions. At the same time, a complete clinical/epidemiological view requires further observational studies to unravel the complex interplay between multiple shared pathogenic mechanisms of diabetes and its complications.
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